Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,051.00GBp
22 Jan 2018
Change (% chg)

8.00 (+0.16%)
Prev Close
5,043.00
Open
5,038.00
Day's High
5,058.00
Day's Low
5,029.00
Volume
409,819
Avg. Vol
2,365,773
52-wk High
5,585.07
52-wk Low
4,136.50

Latest Key Developments (Source: Significant Developments)

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
Thursday, 7 Dec 2017 06:50am EST 

Dec 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT.EAGLE PHARMACEUTICALS- ANTICIPATES COMPLETION OF FULVESTRANT STUDY WITHIN TWELVE MONTHS, AND AN EXPECTED NDA FILING IN Q4 OF 2018.  Full Article

G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer
Tuesday, 28 Nov 2017 07:00am EST 

Nov 28 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER.- ‍FINANCIAL TERMS OF NON-EXCLUSIVE COLLABORATION HAVE NOT BEEN DISCLOSED​.G1 THERAPEUTICS - ‍COLLABORATION TO EVALUATE ASTRAZENECA'S EGFR TYROSINE KINASE INHIBITOR TAGRISSO IN COMBINATION WITH G1'S ORAL CDK4/6 INHIBITOR G1T38​.G1 THERAPEUTICS SAYS IT WILL SPONSOR AND CONDUCT A PHASE 1B/2 STUDY IN COLLABORATION WITH ASTRAZENECA IN PATIENTS WITH NSCLC​.SAYS ‍PLANS TO INITIATE TRIAL IN Q1 OF 2018​.  Full Article

Astrazeneca Plc says EMA accepts Tagrisso submission for 1st-line nsclc
Tuesday, 28 Nov 2017 02:00am EST 

Nov 28 (Reuters) - ASTRAZENECA PLC ::‍EMA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC​.‍EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER​.  Full Article

Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​
Friday, 17 Nov 2017 02:38am EST 

Nov 17 (Reuters) - ALMIRALL SA ::ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​.  Full Article

Astrazeneca says U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma
Tuesday, 14 Nov 2017 06:38pm EST 

Nov 14 (Reuters) - Astrazeneca Plc :Astrazeneca - co, Medimmune, announced that U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma.Astrazeneca - FDA approval based on phase III programme showing up to 51 pct reduction in asthma exacerbations & 75 pct reduction in daily oral steroid use‍​.  Full Article

Astrazeneca says EU approves new indication for Faslodex in combination with palbociclib
Tuesday, 14 Nov 2017 07:24am EST 

Nov 14 (Reuters) - Astrazeneca Plc :FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1.  Full Article

Astrazeneca says Benralizumab receives Positive EU CHMP opinion
Friday, 10 Nov 2017 06:35am EST 

Nov 10 (Reuters) - ASTRAZENECA PLC ::BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA.‍ANNOUNCED THAT CHMP OF EUROPEAN MEDICINES AGENCY HAS ADOPTED POSITIVE OPINION, RECOMMENDING MARKETING AUTHORISATION OF BENRALIZUMAB​.  Full Article

AstraZeneca CEO committed to dividend
Thursday, 9 Nov 2017 07:49am EST 

Nov 9 (Reuters) - AstraZeneca CEO Pascal Soriot says::* committed to dividend "today, tomorrow and day after".  Full Article

AstraZeneca CEO still sees 2023 sales above $40 billion at today's FX
Thursday, 9 Nov 2017 04:43am EST 

Nov 9 (Reuters) - AstraZeneca CEO Pascal Soriot told reporters::working to duplicate quality control systems so can release drugs in EU if hard Brexit.sees high growth rate in China sustainable for next 2-3 years.long term plan confirms we can get to $40-41 billion sales target by 2023 at current exchange rates.  Full Article

‍AstraZeneca Canada says Health Canada has approved Imfinzi for treatment of advanced bladder cancer in previously treated patients​
Monday, 6 Nov 2017 07:59am EST 

Nov 6 (Reuters) - AstraZeneca PLC :‍AstraZeneca Canada says Health Canada has approved Imfinzi for treatment of advanced bladder cancer in previously treated patients​.‍AstraZeneca Canada says Imfinzi has been granted notice of compliance with conditions (noc/c) based on tumour response rate and durability of response​.  Full Article

BRIEF-AstraZeneca's asthma treatment ‍Fasenra approved In Japan​

* ‍FASENRA RECEIVES APPROVAL IN JAPAN​ Source text for Eikon: Further company coverage: (Reporting By London Bureau)